First UK Patient Receives Promising Lung Cancer Vaccine

BioNTech's BNT116 mRNA vaccine aims to improve survival rates for non-small cell lung cancer patients in a groundbreaking trial.

• The vaccine uses mRNA technology similar to Covid-19 vaccines to target cancer cells while sparing healthy cells.
• The phase one trial is being conducted across 34 research sites in seven countries, including the UK.
• Participant Janusz Racz, a 67-year-old scientist, is the first to receive the vaccine in the UK.
• Researchers hope the vaccine will prevent cancer recurrence and enhance the effectiveness of existing treatments.
• BioNTech aims to provide precision cancer immunotherapies to up to 10,000 patients by 2030.

8 Articles

Evening Standard BBC The Guardian Evening Standard The Independent Evening Standard Evening Standard Sky News